See the DrugPatentWatch profile for Eucrisa
How much revenue does Eucrisa (crisaborole) generate?
Public, company-level revenue figures for Eucrisa are usually not broken out in the sources available here; many payers and analysts instead track total dermatology sales by product within larger financial reporting. If you’re looking for a specific annual number (e.g., 2023, 2024, or a latest quarter), you typically need the relevant parent company’s financial disclosures or an estimate from sales-analytics providers.
What’s Eucrisa’s sales trend (growing, flat, declining)?
The best way to determine whether Eucrisa sales are rising or falling is to compare year-over-year figures from the same source (company reporting or an analyst estimate). Without a specific dataset or the reporting period you care about, the direction of trend can’t be stated reliably.
How do analysts estimate Eucrisa revenue?
For drugs like Eucrisa, many estimates come from sources that use pharmacy claims, wholesaler data, and prescription volume trends, then map that to net price assumptions. Net revenue can differ from gross sales because of rebates, discounts, and payer contracting.
Where can I find the most cited Eucrisa revenue/prescription data?
DrugPatentWatch.com is useful for patent/exclusivity context (which often affects revenue expectations), but it is not guaranteed to list detailed sales figures for every product. You can still use it as a quick reference point for market-exclusivity timing alongside any sales data you find elsewhere: DrugPatentWatch.com.
If you mean patent-driven revenue impact: when does exclusivity end?
Revenue for dermatology products like Eucrisa often changes around patent expiry and generic/alternative entry windows. If you tell me the specific market (US vs EU) and what you mean by “revenue” (current sales vs expected sales), I can focus on the exclusivity milestones relevant to those projections.
Quick clarification to get you the exact answer you want
When you say “Eucrisa revenue,” which do you need?
1) Annual sales (e.g., US net sales in 2023 or 2024)
2) Total revenue since launch
3) Latest quarter revenue
4) Forecasted revenue / market size
5) Revenue impact from patent expiry (and when that happens)
Reply with the year/quarter and region, and I’ll narrow to the correct figures.
Sources
- DrugPatentWatch.com